Tristel Share Discussion Threads

[apad] 04/3/2016 16:56

Haven't been able to find any IC comment?
apad

[nehpets81] 04/3/2016 11:28

I don't think he would be buying little chunks in dribs and drabs if he was intending to take the company private as his actions (plus the orchestrated director buying we saw a few days ago) has the effect of boosting the share price. He either sees the shares as cheap or he is trying to create a floor for the share price, I suspect a bit of both.

[bolador] 02/3/2016 18:57

As mentioned before I think that in view of the immense costs of USA market presence and FDA approval this company with its unique product offering would be best placed under the shelter of a bigger health care co. In which case it would make sense if as ceo you owned as much stock as possible. Obviously to comply with the law he cannot know of any likely bidder but when and if he does it will be too late to buy more stock. On the the other hand as Hyrus says he might just think they are cheap.
An agreed take out with a 40% premium to the last option vesting price would make a price of 187p. Just a fairy story for now.

[hydrus] 02/3/2016 18:40

I think he believes it's cheap is all.

[davr0s] 02/3/2016 17:46

It's a bit volatile at the moment - today was good volatility ! (Didn't realise chairman owned so many)

[naos] 02/3/2016 17:13

...chairman again.

What's he up to? He already has more than a quarter of the company, if he keeps buying perhaps he intends to take it private??

Or, perhaps he just thinks cheap SP, so why not.

[pyglet] 02/3/2016 11:15

And another director buy.

[piedro] 02/3/2016 01:03

juuunx2,

Is it not a dirty word?

[juuunx2] 01/3/2016 19:21

Piedro isn't that two words?

[zipstuck] 01/3/2016 14:12

I think one need's to focus on the EPS without share based payments going forward and I share the managements optimisim . The SBP's are a on off in this half. As the trigger point was 134p and alreday accrued I agree with PP there is scope back to 130p. Definitely a stong hold for the future prospects long term. Happy to go to sleep on this one.

[murray80] 01/3/2016 08:22

Piedro

Have you ever a good word to say for Tristel?

[piedro] 29/2/2016 22:13

"There's no doubt they have dropped a big clanger with a badly designed share options scheme"

... dropping 'clangers'
- could the MediChem deal be put in that class?
- they all seem good ideas at the time.

[source] 29/2/2016 21:05

Another update from Paul Scott (turning more positive)...

Regards,
Source.

+++++++++++++

Tristel (LON:TSTL)

Share price: 108.75p (up 4.6% today)
No. shares: 42.2m
Market cap: £45.9m

(at the time of writing, I hold a long position in this share)

Director purchases - I'm really not a fan of orchestrated Director share purchases after bad news, but as mentioned recently for another company, it does seem to work in some situations anyway, in helping to reassure investors. Perhaps it works in marginal situations, where confidence is beginning to return anyway, which is how I see Tristel?

I reported here on 24 Feb 2016 on Tristel's interim results, and the various factors which triggered a sharp correction in the share price. My view, when the shares were at 125p at the time of writing that report, was that the price looked "a bit too high", but that the "longer term upside still looks good".

The share price subsequently dropped considerably more, and went as low as the low-mid 90p's yesterday morning. At around that level, I think it was a reasonably good purchase, so I picked up a few, more of a dabble than a conviction buy.

Management webinar - I was also really impressed with the webinar that TSTL management did with Equity Development yesterday lunchtime. I watched/listened, and felt that management were open in addressing the criticisms of the slowing sales growth, and the share options charge. There's no doubt they have dropped a big clanger with a badly designed share options scheme, but I think they recognise that, and were emphatic that there would be no repetition in the next 3-5 years.

Various other factors mitigate my concerns over the slowing growth rate (now 8%), such as 4% being due to currency effects, and also that low margin products have been dropped - hitting turnover, but having little to no impact on profit.

Overall, I take my hat off to TSTL management for being so open with private investors, and not only holding a webinar, but also a meeting in London, open to private investors. Feedback from this has also been positive. This is outstanding stuff - if only all companies were so willing to engage with their PI shareholder base - especially when contentious issues arise.

TSTL is already being rewarded with a rebound in the share price. I think the glass is slowly turning from half empty, to half full again. The upside from potential US FDA approvals is something that I'd like to stick around for, as that could be a significant catalyst for future growth. I'm not sure there is necessarily much short term upside from here, but who knows? I would have thought it might recover to say 120-130p after a while.

[source] 29/2/2016 07:43

Another buy by the chairman. Big one this time. Regards,Source.

[juuunx2] 27/2/2016 16:51

As I predicted on results day Investors Chronicle rates as a buy for long term growth prospects

[source] 26/2/2016 15:56

That Chinese hospital looks amazing!Regards,Source.

[juuunx2] 26/2/2016 15:32

Piedro :-) it's the weekend

[piedro] 26/2/2016 15:01

juuunx2
"if you don't like the stock xxxxoff and moan somewhere else"

:-(

[piedro] 26/2/2016 15:00

juuunx2
"if you don't like the stock xxxxoff and moan somewhere else"

:-(

[piedro] 26/2/2016 15:00

juuunx2
"if you don't like the stock xxxxoff and moan somewhere else"

:-(

[juuunx2] 26/2/2016 14:54

I agree with APAD and glad I added yesterday far to many negative posters on this board if you don't like the stock xxxxoff and moan somewhere else. Increase in div and profits and very oversold

[mach100] 26/2/2016 14:10

Hi Apad. I don't see many negatives but am happy to hear them. The market likes the buys or sees it is oversold. I think Paul might have been tired as about 33% of the company he has helped to build vanished on paper in two days. It can't be easy to face investors and funds ( by the way they have no preference for one over the other they stated) after the way the market has reacted. But they did and it is strength of character like that gives me extra confidence in the company. The drop is starting to be clawed back and with the froth blown away at least we know where we stand. Those who got out quick on Tuesday can now get more shares than they had on Tuesday for their money. Those that stayed in have a divi to look forward to, a company cash pile to fund it and tempered expectations. A profit warning would whack this. But if this can be avoided we can move on nicely from here. The NHS is a basket case but the company does well overseas and is looking to America so yes I am optimistic.

[tony773] 26/2/2016 14:03

if there was anyway of making a quick quid or 2 it was last night at close of play

[piedro] 26/2/2016 13:41

Xuan Wu Hospital Stella case study
February 2016
Stella reduces capital spend and reprocessing times at Xuan Wu Hospital
Xuan Wu Hospital in Beijing, China was founded in 1958. It is a large Grade 3, Class A hospital providing outpatient services to 4,000 patients every day. ... ...